AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2025
Sep 4, 2025
31100_dirs_2025-09-04_ae73e7e9-3503-413c-b92b-91e02391e35f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-09-02
Reporting Person: GUGGENHIME ANDREW (PRESIDENT AND CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-02 | Common Stock | F | 1270 | $31.56 | Disposed | 131009 | Direct |
| 2025-09-02 | Common Stock | F | 2381 | $31.56 | Disposed | 128628 | Direct |
| 2025-09-02 | Common Stock | F | 1429 | $31.56 | Disposed | 127199 | Direct |
Footnotes
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 24